Table 2. p300 staining and clinicopathological characteristics of 392 melanoma patients.
| Variables | Nuclear p300 | Cytoplasmic p300 | ||||
| low | high | p–value* | low | high | p-value* | |
| All Melanoma | ||||||
| Age | ||||||
| ≤60 | 85 (42.5%) | 115 (57.5%) | .388 | 100 (50.0%) | 100 (50.0%) | .569 |
| >60 | 73 (38.2%) | 118 (61.8%) | 90 (47.1%) | 101 (52.9%) | ||
| Gender | ||||||
| Male | 94 (39.8%) | 136 (60.2%) | .824 | 111 (49.1%) | 119 (50.9%) | .874 |
| Female | 64 (40.9%) | 97 (59.1%) | 79 (48.3%) | 82 (51.7%) | ||
| AJCC stage | ||||||
| I | 41 (32.8%) | 84 (67.2%) | .029 | 81 (64.8%) | 44 (35.2%) | .0005 |
| II | 51 (40.5%) | 75 (59.5%) | 61 (48.5%) | 65 (51.5%) | ||
| III | 33 (55.9%) | 26 (44.1%) | 20 (33.9%) | 39 (66.1%) | ||
| IV | 34 (41.5%) | 48 (58.5%) | 38 (46.3%) | 44 (53.7%) | ||
| Site | ||||||
| Sun Protected | 118 (39.5%) | 181 (60.5%) | .460 | 158 (52.8%) | 141 (47.2%) | .319 |
| Sun Exposed | 41 (44.1%) | 52 (55.9%) | 42 (45.2%) | 51 (55.8%) | ||
| Site (Cases with age >60) | ||||||
| Sun Protected | 54 (38.3%) | 87 (68.1%) | .180 | 67 (47.5%) | 74 (52.5%) | .319 |
| Sun Exposed | 25 (49.0%) | 26 (51.0%) | 25 (49.0%) | 26 (51.0%) | ||
| Primary Melanoma | ||||||
| Age | ||||||
| ≤60 | 45 (37.2%) | 76 (62.8%) | .802 | 71 (58.7%) | 50 (41.3%) | .118 |
| >60 | 47 (36.2%) | 83 (63.8%) | 64 (49.3%) | 66 (50.7%) | ||
| Gender | ||||||
| Male | 54 (38.2%) | 84 (60.8%) | .408 | 74 (53.8%) | 64 (46.2%) | .913 |
| Female | 38 (33.6%) | 75 (66.4%) | 61 (54.0%) | 52 (46.0%) | ||
| Tumor Thickness | ||||||
| ≤2 | 46 (33.6%) | 91 (66.4%) | .306 | 85 (62.0%) | 52 (38.0%) | .003 |
| >2 | 46 (40.4%) | 68 (59.6%) | 50 (45.6%) | 64 (54.4%) | ||
| Ulceration | ||||||
| Absent | 69 (34.8%) | 129 (65.2%) | .251 | 118 (59.6%) | 80 (40.4%) | .093 |
| Present | 23 (43.4%) | 30 (56.6%) | 24 (45.3%) | 29 (54.7%) | ||
| Subtype | ||||||
| Acrolentigous | 4 (50.0%) | 4 (50.0%) | .556 | 2 (25.0%) | 6 (75.0%) | .603 |
| Lentigous | 18 (41.9%) | 25 (58.1%) | 24 (55.8%) | 19 (44.2%) | ||
| Nodular | 18 (40.0%) | 27 (60.0%) | 25 (55.6%) | 20 (44.4%) | ||
| Spindle type | 4 (40.0%) | 6 (60.0%) | 7 (70.0%) | 3 (30.0%) | ||
| Superficially spreading | 25 (28.7%) | 62 (71.3%) | 50 (57.5%) | 37 (42.5%) | ||
| Unspecified | 23 (39.7%) | 35 (60.3%) | 33 (56.9%) | 25 (43.1%) | ||
| Metastatic Melanoma | ||||||
| Age | ||||||
| ≤60 | 39 (49.4%) | 40 (50.6%) | .492 | 29 (36.7%) | 50 (63.3%) | .409 |
| >60 | 27 (43.5%) | 35 (56.5%) | 27 (43.5%) | 35 (56.5%) | ||
| Gender | ||||||
| Male | 41 (44.1%) | 52 (55.9%) | .843 | 38 (40.9%) | 55 (59.1%) | .798 |
| Female | 22 (45.8%) | 26 (54.2%) | 18 (37.5%) | 30 (62.5%) | ||
Sun-protected sites: trunk, arm, leg and feet; Sun-exposed sites: head and neck.
*
χ2 test.